A lot of the growth in Zytiga sales is overseas, where imo Astellas has done a poor job competing. Maybe new VP from AstraZenica will change that.
It's impressive JNJ sales reps can still sell any Zytiga since Xtandi is so much better. Have to remember many folks have already started on Zytiga before Xtandi was approved pre-chemo. I doubt doctors would switch these individuals off.
No way, Zytiga sales were $595 million in 4th qtr. ww. Zytiga was outselling Xtandi about 2 to 1 with Xtandi fast closing the gap. So the question becomes how much did Xtandi close that gap.
Absolutely means sales for Xtanid are going up. Both companies have said recently that the overall market for prostate cancer drugs is growing at a double digit clip. My only real questions is how soon we'll see international sales ramp up. I think Astellas is behind on that front (their responsible for international sales). Astellas just hired a new VP of global development operations from AstraZenica this month to crank up international sales.
Up 20.9% from 211m Q4 2013 to 255m Q4 2014.
Full year 2014 971 million $ (750 million in 2013)
WW sales in 2014 2237 million $.
Looks like Zytiga Growth is fading out...
Also JNJ reports on Jan. 20 and we'll see sales of Zytiga. Zytiga sales could still be growing, but at a much slower rate, since the overall market for prostate cancer drugs is rising at double digit rates, will be interesting what JNJ says about Zytiga sales.
Astellas reports on Feb. 2nd, we'll see Xtandi sales numbers and MDVN will move one way or the other (might wrack my brain for a call strategy on that one). I'll be watching ww sales on that one closely, we should start to see a ramp up in Europe and Japan with the expanded label.
Thanks, I upvoted up because it's good news even considering it comes from Goldman who are some of the WORST analysts in biotech. ;)
But the numbers from Zytiga might surprise on the upside since per both JNJ in October and MDVN (CEO at JPM Healthcare Conf. Jan. '15) say that the overall market for prostate cancer drugs is growing at double digit rates. So Zytiga might not dive as much as some expect since the overall market is growing at double digit rates as well. Still I expect that Xtandi will overtake Zytiga either late 2015 or early 2016 in ww sales with the expanded label.
The goldman Sachs analyst downgraded JNJ this morning, citing increasing competition for several of their drugs. In addition to Olysio being hurt by the new Gilead HepC drugs, she mentioned that "Zytiga is being increasingly constrained by Xtandi". Since I assume that Goldman has access to IMS, all the other script numbers and multiple proprietary sources, I take this as confirmation that Xtandi is continuing to grab market share.
Listened to the JPM presentation - it was only archived as "audio only" (= no slides). Actually, Hung stated that as of the third quarter of 2014, the annualized run rate was $1.2 billion. Their marketing survey indicates that 90% of US urologists were now familiar with Xtandi. He also indicated that Xtandi may find application in breast cancers other than triple negative bc.
Thanks. I will go to the corporate site and see if I can get the archived rebroadcast of their presentation.
Hi, Durango, Unfortunately, Credit-Suisse's weekly posting of IMS numbers for recently launched drugs is no longer available on the Schwab research site. However, the numbers are obviously widely available to the investment banks and brokerages and I'd guess that this stock's strength here means that they look good.